Sep 13, 2021
Matt Kaeberlein is globally
recognized for his research on the biology of aging and is a
previous guest on The Drive. In this episode, Matt defines aging,
the relationship between aging, chronic inflammation, and the
immune system, and talks extensively about the most exciting
molecules for extending lifespan. He discusses the current state of
the literature of testing rapamycin (and rapalogs) in animals and
humans, including Matt’s Dog Aging Project, and provides insights
into how we can improve future trials by conceptualizing risk,
choosing better endpoints, and working with regulators to approve
such trials. He also examines the connection between aging and
periodontal disease, biomarkers of aging, and epigenetic clocks.
Finally, they explore some of the biological pathways involved in
aging, including mTOR and its complexes, sirtuins, NAD, and NAD
precursors.
We
discuss:
- The various definitions of aging
[3:25];
- The relationship between disease
and the biology of aging [16:15];
- Potential for lifespan extension
when targeting diseases compared to targeting biological aging
[22:45];
- Rapamycin as a longevity agent
and the challenges of targeting the biology of aging with molecules
[32:45];
- Human studies using rapalogs for
enhanced immune function [39:30];
- The role of inflammation in
functional declines and diseases of aging
[50:45];
- Study showing rapalogs may
improve the immune response to a vaccine
[56:15];
- Roadblocks to studying
gero-protective molecules in humans [1:01:30];
- Potential benefits of rapamycin
for age-related diseases—periodontal, reproductive function, and
more [1:12:15];
- Debating the ideal length and
frequency of rapamycin treatment for various indications like
inflammation and longevity [1:21:30];
- Biomarkers of aging and
epigenetic clocks [1:29:15];
- Prospects of a test that could
calculate biological age [1:37:45];
- The Dog Aging Project testing
rapamycin in pet dogs [1:42:30];
- The role of the mTOR complexes
[1:58:30];
- mTor inhibitor called Torin2,
mitochondrial disease and other potential pathways
[2:09:45];
- Catalytic inhibitors, sirtuins,
and NAD [2:19:15];
- NAD precursors: help or hype?
[2:28:15]; and
- More.
Learn more: https://peterattiamd.com/
Show notes page for this episode: https://peterattiamd.com/MattKaeberlein2
Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/
Connect with Peter on Facebook | Twitter | Instagram.